摘要: The highlighting of predictive and/or prognostic biomarkers has enabled major advances in recent years in oncology, to define new therapeutic targets and better use of some existing treatments. Many translational researches are being conducted in pancreatic adenocarcinoma and could ultimately help to better define treatment options for a given patient. Predictive biomarkers of the efficacy of gemcitabine, fluoropyrimidines, platinum salts, and erlotinib have been proposed in recent years and are discussed in this review. hENT1 expression evaluated with the mouse antibody is now the best validated biomarker with a strong predictive value for the efficacy of adjuvant gemcitabine, but this antibody is currently unavailable. The rabbit antibody has no predictive value. The other most promising predictive biomarkers are the expression of TS and/or the DPD for fluoropyrimidines efficacy and the expression of …